fbpx
José García-Tirado on his diabetes research: Interview

José García-Tirado on his diabetes research: Interview

José García-Tirado on his diabetes research: Interview

DCB assistant professor José García-Tirado recently gave an interview on his diabetes research, providing insights into his career and the road that led him to Berne. You can now read the interview in German and French in the Swiss medium “d-journal”.

Interview with José García-Tirado on his diabetes research

Recently, the Swiss d-journal – a medium of the Swiss diabetes organisation diabetesschweiz – published an interview with DCB assistant professor José García-Tirado.

Since the beginning of 2023, José has been a professor specialising in diabetes technology at the University Department of Diabetology, Endocrinology, Nutritional Medicine and Metabolism (UDEM) and at the DCB (Diabetes Center Berne). Together with his team, he is involved in the development of even more precise therapies such as closed-loop systems for people with diabetes and other metabolic diseases.

In his interview, José speaks about his motivation for and background in diabetes research, and where he aims to take it in the next few years.

The interview is available as d-journal articles in German and French, and in our newsletter in English. Enjoy the read!

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

SNAQ and CarbVis join forces for better carb counting in diabetes

SNAQ and CarbVis join forces for better carb counting in diabetes

SNAQ and CarbVis join forces for better carb counting in diabetes

Bern, 3 October 2023 – SNAQ and CarbVis join forces for better diabetes management. CarbVis AG will be integrated into SNAQ AG, aiming to gain faster access to the market and to support the lives of people with diabetes more effectively. The new constellation enables the respective strengths to be used even better. The precise assessment of carbohydrates before each meal and their influence on blood glucose levels remain of central importance.

For people living with diabetes, estimating the amount of carbohydrates for appropriate insulin dosing is like a gamble sometimes. Decisions are often made based on experience and gut feeling, which can lead to mistakes1 with health consequences. For both CarbVis and SNAQ, the goal was to develop a technology that enables a quick and, above all, reliable calculation in a user-friendly way.

The two companies started with a different focus and have developed accordingly. SNAQ has an international focus and is now an established solution on the market. CarbVis emerged from a DCB-funded translational project in 2021, in collaboration with the University Department of Diabetology, Endocrinology, Nutritional Medicine and Metabolism (UDEM) of the Inselspital Bern and the University of Bern. After several years of technical and regulatory development, CarbVis has had a class 1 MDD medical device certified. In addition, the documents for the approval of a class 2 MDR medical device were submitted. The Qarbs app developed by CarbVis focused on safety and accuracy to achieve ease of integration with customers at B2B level. This complements SNAQ’s market presence and experience and extends the offering to B2C and B2B customers.

Added value for app users

“Uniting the two platforms is a logical development for us – we bring together our different strengths as well as business strategies and thus achieve a clear qualitative added value for the users of the app, medical professionals and our B2B partners,” emphasises the CEO of DCB and designated Chairman of the Board of Directors of SNAQ, Derek Brandt.

“The integration of CarbVis’ extensive regulatory and technical work will enable SNAQ to bring a dedicated insulin dosing solution to the European and US markets significantly faster,” said SNAQ CEO Aurelian Briner.

Image source: SNAQ

1 Buck S, Krauss C, Waldenmaier D, Liebing C, Jendrike N, Högel J, Pfeiffer BM, Haug C, Freckmann G. Evaluation of Meal Carbohydrate Counting Errors in Patients with Type 1 Diabetes. Exp Clin Endocrinol Diabetes. 2022 Jul;130(7):475-483. doi: 10.1055/a-1493-2324. Epub 2021 May 25. PMID: 34034353.

About DCB

Diabetes Center Berne (DCB) is a private, independent Swiss foundation established in 2017 with the aim of making life with diabetes easier. DCB supports ideas and projects in the field of diabetes technology worldwide by providing expertise, access to clinical research facilities and its own laboratories, as well as financial resources. The aim is to bring them a big step closer to market entry in a collaborative partnership. The work of the DCB is non-profit – the goal is new insights and innovations around diabetes management as well as a vibrant community.

About SNAQ

SNAQ’s diabetes platform enables patients and professionals to make data-based decisions around meals. The patented image analysis technology for estimating carbohydrates in meals has been validated in clinical trials and submitted for approval as a medical device in Europe. In the US, SNAQ is already an established solution with over 70,000 users.

Downloads

More recent news

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

Greta Ehlers and Dr. Stefanie Hofer: Research & Patient Centricity

Greta Ehlers and Dr. Stefanie Hofer: Research & Patient Centricity

Greta Ehlers and Dr. Stefanie Hofer: Research & Patient Centricity

Recently, Greta Ehlers from our Business Development Team and Dr. Stefanie Hofer from our Clinical Research Team joined Tinotenda Dzikiti on his podcast “The Diabetic Mogul”, talking about research and patient centricity at DCB.

Research and Patient Centricity at DCB

In this podcast episode, Greta Ehlers and Dr. Stefanie Hofer from the DCB team give insights into their own lives with type 1 diabetes as well as their professional backgrounds in the diabetes field. In doing so, they specifically delve into the research we do at DCB and our strong commitment to patient centricity.

You can listen to the podcast below:

    About “The Diabetic Mogul” podcast

    “The Diabetic Mogul Podcast”, is hosted by Tinotenda Dzikiti (Certified Diabetes Educator) and Konstantina Taki (Medical Doctor) and who are Patient Advocates. Both Tino & Konna are co-hosting a series of podcast episodes, as they envision to inspire, empower, encourage and educate the community to prevent/manage diabetes. Their hope is that “everyone could get involved, get engaged, and come up together to create the change that this World needs.”

      More recent news

      Sign up for our newsletter and stay up to date.

      * Pflichtfelder
      DSGVO *

      DCB Research AG

      Freiburgstrasse 3
      3010 Bern
      Switzerland

      DCB on ADA TV: Driving Diabetes Technology Innovation

      DCB on ADA TV: Driving Diabetes Technology Innovation

      DCB on ADA TV: Driving Diabetes Technology Innovation

      As the American Diabetes Association’s 83rd Scientific Session are being held in San Diego, CA, from 23-26 June, a short movie about DCB’s mission of driving diabetes technology innovation will be broadcast across the convention center as well as conference hotels and shuttle busses.

      Learn more about DCB’s mission on ADA TV

      During the American Diabetes Association’s 83rd Scientific Session, a short movie about DCB’s mission will be broadcast across the convention center and associated areas. The movie produced for ADA TV features employees as well as associated research teams of DCB and brings the mission of driving diabetes technology innovation to screens all over.

      Other than on-site at the American Diabetes Association’s 83rd Scientific Sessions, it is also available to watch online:

      DCB thanks the American Diabetes Association and the production company WebsEdge Medicine for this great collaboration and for giving the DCB mission a stage at the ADA congress.

      More recent news

      Sign up for our newsletter and stay up to date.

      * Pflichtfelder
      DSGVO *

      DCB Research AG

      Freiburgstrasse 3
      3010 Bern
      Switzerland

      Start-up funding in diabetes technology: DCB Innovation Challenge enters new round 

      Start-up funding in diabetes technology: DCB Innovation Challenge enters new round 

      Start-up funding in diabetes technology: DCB Innovation Challenge enters new round 

      For the third time, the Diabetes Center Berne is launching the Open Innovation Challenge with the aim of specifically promoting innovative projects in the field of diabetes management on Swiss and international level. Participating start-ups benefit from professional expert feedback, and the three best projects in each of the categories Diabetes Devices and Digital Diabetes receive access to a bootcamp. The finalists will receive prize money of up to USD 100,000 and further support from the DCB. The DCB Innovation Challenge is the world’s largest diabetes technology award with international appeal.

      More than 537 million people worldwide live with diabetes, which means a constant challenge in everyday life for those affected. Technological innovations make an important contribution to making it easier to deal with diabetes – whether it is measuring glucose levels or now even planning the amount of insulin needed via an app. But despite these enormous advances in diabetes technology, there is still a great, unmet need for innovative technical solutions. These should help to ease the challenge for users in everyday life and improve the lives of people with diabetes in the long term.

      Two categories: Diabetes Devicesand “Digital Diabetes

      In the last edition of the Open Innovation Challenge 2022, start-ups GO-Pen from Denmark and Una Health from Germany were named winners in their respective categories. GO-Pen is developing a cost-effective, reliable and sustainable insulin pen, while Una Health enables people with type 2 diabetes to understand the causes of their condition and make simple and targeted changes to improve their health.

      In the new edition of the Innovation Challenge 2023, there are again two categories: on the one hand for medical devices, such as insulin pens, insulin pumps or sensors for continuous glucose measurement. The other is for digital solutions such as apps for diabetes management, which can include monitoring glucose levels, nutrition and exchanging information with other people with diabetes. For the category “Diabetes Devices”, the kick-off will be at the beginning of May 2023, “Digital Diabetes” will start at the beginning of June 2023. After a first round and feedback from the expert jury, the top 20 will enter a mentoring programme. The three best projects will be invited to a bootcamp individually tailored to them. On 9 November 2023, the winning project will be selected by an international jury and rewarded with 100,000 USD including in-kind support such as coaching. Second and third place will each receive USD 20,000 including further support. The DCB Open Innovation Challenge is thus the world’s largest diabetes technology award with international appeal. Start-ups, medical and research professionals, but also individuals can apply.

      Closing gaps with a translational approach

      “At the DCB, we want to close the gaps between ideas, clinical trials and start-ups through innovation.  We are also pursuing this goal with the DCB Open Innovation Challenge, which connects start-ups, mentors, corporates and the international diabetes community. In this way, we can help real innovative ideas in diabetes management to achieve a breakthrough. Not only with funding, but also with targeted support from our partner network,” says Dr Maren Schinz, responsible for the DCB Open Innovation Challenge.

      Do you have an innovative idea to facilitate change diabetes management forever? Want to see how your idea becomes reality? Do you have valuable insights to help co-create the diabetes technology of tomorrow? Do you have feedback to share with others in the community? Then sign up to our Innovation Platform and participate in the DCB Open Innovation Challenge 2023! You can find more information here.

      Media release

      PDF, 437.68 KB

      Innovation Challenge 2023

      Information sheet

      More recent news

      Sign up for our newsletter and stay up to date.

      * Pflichtfelder
      DSGVO *

      DCB Research AG

      Freiburgstrasse 3
      3010 Bern
      Switzerland

      José Garcia-Tirado takes up position as professor specialising in technology-assisted precision medicine

      José Garcia-Tirado takes up position as professor specialising in technology-assisted precision medicine

      José Garcia-Tirado takes up position as professor specialising in technology-assisted precision medicine

      The newly created assistant professorship with tenure track is the second of a total of three professorships in the field of “Diabetes Technology and Artificial Pancreas” jointly created by the University of Bern, the Inselgruppe and the Diabetes Center Berne (DCB).

      Focus on fully automated insulin delivery

      Before taking up his new position, Garcia-Tirado was an assistant professor at the University of Virginia. His research focuses on fully automated insulin delivery, also called artificial pancreas or closed-loop system, as well as conducting corresponding clinical trials.

      “I am very excited to contribute to the field of diabetes technology as part of the joint venture between the University of Bern Clinic for Diabetology, Endocrinology, Nutritional Medicine and Metabolism (UDEM) and the Diabetes Center Berne (DCB) by developing new intelligent algo- rithms for automated insulin delivery and decision support systems for people with diabetes,”says Garcia-Tirado.

      Derek Brandt, CEO of the DCB adds: “In addition to Lilian Witthauer, professor in the field of sensor technology, we have taken a second and important step with Professor Garcia-Tirado for the topic of closed-loop systems. This enables us to play an international pioneering role in the field of translational diabetes technology research. We are doing everything we can to further improve daily life for people with diabetes“.

      José Garcia-Tirado

      More recent news

      Sign up for our newsletter and stay up to date.

      * Pflichtfelder
      DSGVO *